For a US supplement brand, phosphatidylserine is a familiar ingredient with an established place on the market. The first time most buyers confront the EU question is when a European distributor, retailer, or contract manufacturer asks a single short question: what is the novel food status of this ingredient? The answer determines whether the material can be lawfully placed on the EU market, how it must be labeled, and how long market entry will take. Yet status is not a checkbox on a certificate of analysis — it is a classification judgment built on the ingredient's composition, process, and documented history. This guide explains the framework, why PS status is more nuanced than many suppliers suggest, and exactly what to request from a supplier before committing to an EU launch.
The EU Novel Food Framework in Brief
Regulation (EU) 2015/2283 governs novel foods in the European Union. Its core rule is simple: a food or food ingredient that was not used for human consumption to a significant degree within the EU before 15 May 1997 may only be placed on the market if it appears on the Union list of authorized novel foods or an authorization application succeeds. The regulation also provides a notification route for foods with a demonstrated history of safe use in a third country — a scientifically assessed pathway, not a paperwork formality.
Two supporting resources matter for buyers. The European Commission maintains a Novel Food Catalogue, an informal but influential reference that lists how various substances have been viewed by member states. Separately, EFSA carries out the scientific risk assessment behind each authorization request. Neither resource substitutes for a legal assessment of your specific ingredient, but both shape how authorities will look at it.
Where Phosphatidylserine Sits: Why Status Is Not a Simple Yes/No
Phosphatidylserine does not present as a single, uniform substance. It is a phospholipid class, commercially produced through different routes with materially different regulatory profiles:
Source and process matter. PS derived from soy lecithin through enzymatic transphosphatidylation is the dominant commercial form, but the enzyme system, substrate, and purification steps define the final composition. Two PS powders with the same 50% assay can differ in phospholipid spectrum, residual substrates, and carrier — differences that matter for a novel food assessment because the assessment runs on the specific food, not the name on the drum.
Historic use is the pivot point. Lipid fractions such as lecithin have long-standing food use in the EU, which supports the argument that certain phospholipid-rich materials fall outside the novel food definition. But concentrated, enzyme-modified PS is a distinct proposition from generic lecithin, and member states have historically taken differing views on where the line sits. The practical conclusion: status is ingredient-specific. It attaches to your supplier's specific material, process, and documentation — not to "phosphatidylserine" as a category.
What "History of Safe Use" Means for Your Ingredient
The notification pathway for third-country foods requires demonstrating that the food and its use have been safe across a meaningful period in a comparable population. In practice, a history-of-safe-use argument for PS rests on several evidence layers:
- Documented human consumption of the ingredient (or a closely equivalent material) in a third country before and after the 1997 cutoff, at intake levels comparable to the proposed EU use.
- Composition and specification data showing the material assessed is the material consumed historically.
- Toxicological and safety literature consistent with the proposed use levels.
- National approvals or notifications in third countries, which strengthen but do not replace the EU-specific argument.
Buyers should be skeptical of two failure modes. The first is circularity — citing an ingredient's own marketing history as evidence of safe use. The second is material mismatch — using safety data from a soy-derived PS when the supplier's material is sunflower-derived, or from a 20% grade when you are buying a 70% concentrate. Each layer of the argument must match the actual product.
Supplier Documentation That Answers the Status Question
A well-prepared PS supplier should be able to hand you a status dossier without prompting. At minimum, request:
- A written regulatory position statement from the manufacturer identifying the legal basis on which they consider the material marketable in the EU, with reasoning — not just a conclusion.
- Full process description from source through final powder, sufficient to compare against any historical-use or catalogue references.
- Composition data beyond the headline assay: phospholipid spectrum, carrier identity, and impurity profile.
- Any third-country regulatory history: national notifications, authorizations, or expert evaluations.
- If an authorization or notification exists for this specific material, the reference and scope — and confirmation that your purchase specification falls within that scope.
If a supplier cannot produce item 1 in writing, treat the EU question as open regardless of what their sales deck says.
US Perspective: Why GRAS or NDI Is Not an EU Answer
US buyers often assume a GRAS determination or a completed NDI notification travels with the ingredient. It does not. The US framework evaluates safety under US law and definitions; the EU framework runs on its own cutoff date, its own Union list, and its own assessment criteria. A material can be lawfully marketed in the US and still require an EU authorization or notification pathway — and vice versa. When sourcing from a US-facing supplier for EU distribution, ask specifically about EU status evidence. Suppliers who sell meaningfully into Europe will have it; suppliers who have never shipped to the EU typically will not.
Consequences for Labeling and Market Entry
Status drives downstream decisions. An authorized novel food may carry specified conditions of use, maximum levels, or labeling requirements written into its authorization. A notification-route product must be marketed consistently with the notified use. And a product that fails both routes cannot be placed on the market at all until authorization is obtained — a process measured in years, not weeks, and one that is realistically pursued by the ingredient owner, not by an individual brand buyer. Build the status review into your sourcing timeline before, not after, supplier selection.
자주 묻는 질문
Is phosphatidylserine authorized as a novel food in the EU?
Status is ingredient-specific and evolves. Some phospholipid materials have long-standing use in the EU food supply, while concentrated or enzyme-modified products may fall under Regulation (EU) 2015/2283. Do not rely on a categorical answer from any source — request a written regulatory position from your supplier for the specific material and confirm your interpretation with your national competent authority or a regulatory consultant.
Can I sell a PS supplement in the EU if it is GRAS in the US?
No conclusion can be drawn from GRAS status alone. GRAS is a US framework determination; EU marketability depends on the novel food rules with their own criteria and cutoff date. You need EU-specific evidence for the specific material you are buying.
What is the first document I should request from a PS supplier for the EU?
A written regulatory position statement from the manufacturer explaining the legal basis for EU marketability of their specific material. If it cannot be produced, the EU question is unresolved regardless of other marketing claims.
Does the EU Novel Food Catalogue have legal force?
No. The catalogue is an informal reference tool reflecting views exchanged between member states and the Commission. It is persuasive and useful, but a definitive status judgment for your ingredient requires assessment of the specific material and process.
Who applies for novel food authorization — the brand or the supplier?
Authorization applications are realistically prepared and owned by the ingredient manufacturer or the holder of proprietary data, since they require technical dossiers and safety data. A brand buyer typically relies on an existing authorization or notification, confirming its scope covers their intended use.
결론
Phosphatidylserine's EU novel food status is not a label on a drum — it is an ingredient-specific judgment that depends on source, process, composition, and documented history of use. For US and EU buyers, the reliable path is procedural: ask for the supplier's written regulatory position, verify that safety and history evidence matches the material you are actually purchasing, and close the status question before formulation and artwork lock in your dependence on the ingredient. Brands that treat status as a sourcing criterion, rather than a post-purchase surprise, launch in Europe on schedule and without regulatory debt.
출처
- European Commission — Novel Food: https://ec.europa.eu/food/safety/novel-food_en
- European Commission — Food Safety: https://food.ec.europa.eu/
- US FDA — Dietary Supplements: https://www.fda.gov/food/dietary-supplements
- World Health Organization — Food Safety: https://www.who.int/health-topics/food-safety
추천 다음 단계
- 검토 포스파티딜세린 제품 페이지.
- 비교 두두 PS 그리고 선바라기 PS.
- 체크 제조 증명 그리고 품질 및 연구개발.